An investor in Esperion Therapeutics Inc (NASDAQ:ESPR) filed a lawsuit over alleged violations of Federal Securities Laws by Esperion Therapeutics Inc.
Investors who purchased shares of Esperion Therapeutics Inc (NASDAQ:ESPR) have certain options and for certain investors are short and strict deadlines running. Deadline: March 14, 2016. Esperion Therapeutics Inc (NASDAQ:ESPR investors should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
Ann Arbor, MI based Esperion Therapeutics Inc is a pharmaceutical company that focuses on developing and commercializing oral low-density lipoprotein cholesterol (“LDL-cholesterol”) lowering therapies for patients with hypercholesterolemia. Esperion Therapeutics’ lead product candidate is ETC-1002, a once-daily small molecule designed to lower LDL-cholesterol levels.
The plaintiff alleges on behalf of purchasers of Esperion Therapeutics Inc (NASDAQ:ESPR) common shares between August 18, 2015 and September 28, 2015, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between August 18, 2015 and September 28, 2015 defendants issued false and misleading statements and/or failed to disclose adverse information regarding Esperion’s business and prospects, including that there was no clear path to approval for ETC-1002, and that the FDA had encouraged the Company to initiate a cardiovascular outcomes trial (“CVOT”) and that completion of a CVOT could be necessary prior to approval of ETC-1002. As a result of these false statements and/or omissions, Esperion common stock traded at artificially inflated prices during the Class Period, reaching as high as $82 per share in intra-day trading.
On August 17, 2015, Esperion Therapeutics Inc reported material events from an early August 2015 meeting with the U.S. Food and Drug Administration (“FDA”) regarding the next phase of the approval process for ETC-1002. Esperion Therapeutics Inc stated that during the meeting it was informed by the FDA that Esperion Therapeutics Inc would not have to complete a CVOT to gain approval of ETC-1002. Esperion Therapeutics Inc also informed investors that it had a “‘clear regulatory path forward for development and approval of ETC-1002.’”
On September 28, 2015, Esperion Therapeutics Inc provided an update on the design and timing of its planned pivotal Phase 3 clinical development program following receipt of the official End-of-Phase 2 Meeting Minutes from the FDA. Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) declined to as low as $18.07 per share on September 29, 2015, respectively $12.61 per share on January 20, 2016.
Those who purchased shares of Esperion Therapeutics Inc (NASDAQ:ESPR) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego